Sensorion strives to be the first to bring effective drug candidates to patients with inner ear disorders. 

Our efficient, in-house, Research and Development platform:
 - Was developed based on our scientific expertise and years of international research on the inner ear, 
 - Incorporates the most recent scientific advances for in vitro and functional cellular ex vivo assays, in-vivo disease models, pharmacokinetics & pharmacodynamics and toxicology studies,
 - Allows for a reproducible process for developing next-generation products,
 - Is dedicated to discovering first-in-class drug candidates for dysfunctions of the inner ear.

plateform

Latest news

  • 27 Mar 2019

    Sensorion reports its 2018 annual results. 75% of patients enrolled in the Sens-111 clinical trial. Read

  • 11 Mar 2019

    Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management. Bpifrance has selected Sensorion for its program "Hub Health Tech". Read

Patient center

Corporate presentation